HIV Nef-M1 Effects on Colorectal Cancer Growth in Tumor-induced Spleens and Hepatic Metastasis.
CXCR4 receptors have been implicated in tumorigenesis and proliferation, making it a potential target for colorectal cancer therapy. Expression of this chemokine receptor on cellular surfaces appears to promote metastasis by directly stimulating tumor cell migration and invasion. The receptor/ligand, CXCR4/SDF-1alpha, pair are critically important to angiogenesis and vascular remodeling which supports cancer proliferation. Our work has shown that a novel apoptotic peptide of HIV-1, Nef-M1, can act as a CXCR4 antagonist, inducing apoptosis in CXCR4 containing cells. Four colorectal tumor cell lines (HT-29, LS174t, SW480, WiDr), were evaluated for their response to Nef-M1 peptide via in vivo and in vitro. The presence of CXCR4 receptors on tumor cells was determined using immunohistochemical and RT-PCR analyses. Solid xenografts derived from tumor cell lines grown in SCID mice, were evaluated for the persistence of the receptor. Xenografts propagated in SCID mice from each of the four cell lines demonstrated high levels of receptor expression as well. The effects of Nef-M1 in vivo via splenic injected mice and subsequent hepatic metastasis also demonstrated dramatic reduction of primary tumor growth in the spleen and secondary invasion of the liver. We concluded that Nef-M1 peptide, through physical interaction(s) with CXCR4, drives apoptotic reduction in in vivo primary tumor growth and metastasis.
Harrington
Willie
W
Department of Surgery, Morehouse School of Medicine, Atlanta, Georgia.
Bond
Vincent
V
Huang
Ming Bo
MB
Powell
Michael
M
Lillard
James
J
Manne
Upender
U
Bumpers
Harvey
H
J Exp Med. 1996 Sep 1;184(3):1101-9
9064327
Clin Cancer Res. 2000 Sep;6(9):3530-5
10999740
Curr Top Microbiol Immunol. 1999;237:1-30
9893343
J Natl Cancer Inst. 1990 Jan 3;82(1):4-6
1688381
J Virol. 2004 Oct;78(20):11084-96
15452229
Biomed Pharmacother. 2006 Jul;60(6):273-6
16828253
Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9448-53
9689100
Nature. 1996 Aug 29;382(6594):829-33
8752280
J Surg Res. 1996 Feb 15;61(1):282-8
8769979
Cancer Biol Ther. 2005 Jan;4(1):65-9
15662115
Breast Cancer Res. 2003;5(5):R144-50
12927045
Nature. 1998 Jun 11;393(6685):591-4
9634237
Blood. 2002 Apr 15;99(8):2703-11
11929756
Genomics. 1993 Jun;16(3):707-12
8325644
Cancer Res. 2003 Jul 1;63(13):3833-9
12839981
Endocr Rev. 1997 Feb;18(1):4-25
9034784
Nature. 1998 Jun 11;393(6685):595-9
9634238
Cancer Metastasis Rev. 1993 Sep;12(3-4):325-43
8281616
J Exp Med. 1997 Oct 20;186(8):1389-93
9334379
Cancer Res. 2004 Jun 15;64(12):4302-8
15205345
Nature. 1996 Aug 15;382(6592):635-8
8757135
Immunol Lett. 2001 Aug 1;78(1):29-34
11470148
Cancer J. 2000 May;6 Suppl 3:S225-36
10874492
J Cell Biochem. 2003 Jun 1;89(3):462-73
12761880
J Virol. 2004 Mar;78(6):3099-109
14990729